Federal Govt Schedules Potent Kratom Derivatives as Schedule I Opioids
On August 25, 2026, the DOJ classified three kratom derivatives as Schedule I opioids.
Why it matters: This emergency scheduling subjects companies that manufacture or distribute these compounds to strict federal controls, increasing regulatory and legal risks. Compliance and regulatory teams must reassess product lines containing these substances to avoid enforcement actions.
- DOJ announced emergency scheduling of mitragynine pseudoindoxyl (MGPI), MGM-15, and MGM-16 on August 25, 2026.
- DEA places these compounds in Schedule I due to potent opioid effects and risks like dependence and respiratory depression.
- The scheduling applies only to synthetic and concentrated kratom derivatives, not traditional botanical kratom.
- Products with more than 0.050% 7-hydroxymitragynine (7-OH) or over 1 mg per unit are also temporarily scheduled under DEA's July 6, 2026 rule.
On August 25, 2026, the U.S. Department of Justice (DOJ) announced it is placing three synthetic kratom-derived compounds—mitragynine pseudoindoxyl (MGPI), MGM-15, and MGM-16—into Schedule I of the Controlled Substances Act on an emergency basis. The Department aims to curb emerging public health risks stemming from these potent opioid analogs linked to the kratom plant, native to Southeast Asia.
The Drug Enforcement Administration (DEA) action targets manufactured products containing these compounds due to their strong mu-opioid receptor agonist activity, which carries risks of dependence and respiratory depression. According to the DOJ, these substances pose dangers similar to other Schedule I opioids, mandating stringent federal controls on their manufacture, distribution, and possession. The DOJ statement emphasized that "these are potent opioids being manufactured and sold in consumer products, often under labels that obscure their true risks," highlighting concerns over potential abuse.
This emergency scheduling does not apply to traditional botanical kratom products. The DOJ has said it will exercise enforcement discretion when only incidental trace amounts of MGPI are found in botanical kratom products. However, this discretion does not extend to MGM-15, MGM-16, or any product with manufactured, fortified, or intentionally added MGPI.
Separately, the DEA published a temporary scheduling rule in the Federal Register on July 6, 2026, covering concentrated 7-hydroxymitragynine (7-OH) products. Under this rule, products exceeding 0.050 percent of 7-OH by dry weight or more than 1 milligram per finished unit fall under Schedule I controls as well.
Legal compliance teams at companies involved with kratom-derived products need to closely review manufacturing processes and product formulations to ensure adherence. Failure to comply with Schedule I controls could lead to enforcement actions. The DOJ's policy also clarifies it has not changed the scheduling status of other substances and maintains the FDA's regulatory authority over kratom products.
By the numbers:
- August 25, 2026 — DOJ emergency scheduling announcement date
- 0.050% — 7-hydroxymitragynine dry weight threshold for scheduling
- 1 mg — Finished unit limit for 7-hydroxymitragynine triggering Schedule I control
Yes, but: The scheduling excludes traditional botanical kratom and allows enforcement discretion for incidental MGPI traces, limiting immediate impact on all kratom products.
What's next: Industry and legal observers await detailed enforcement guidelines and potential litigation regarding classification and compliance obligations for kratom derivatives.